Skip to main content

Advertisement

SpringerLink
Log in

Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Autoimmune hepatitis (AIH), primary biliary cirrhosis, and primary sclerosing cholangitis are the three major autoimmune diseases affecting the liver, and of these three, AIH is the most typical autoimmune disease being characterized by a T-cell-rich infiltrate, raised circulating γ-globulins, autoantibodies, HLA associations, and links with other autoimmune diseases. It is the only one, of the three diseases, that responds well to immunosuppressive therapy. AIH is caused by dysregulation of immunoregulatory networks and the consequent emergence of autoreactive T cells that orchestrate a progressive destruction of hepatocytes leading untreated to liver failure. T cells play a major role in the immunopathogenesis, and both CD4+ and CD8+ T cells are involved together with effector responses mediated by NK cells, γδ T cells, and macrophages. A number of triggering factors have been proposed including viruses, xenobiotics, and drugs, but none have been conclusively shown to be involved in pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43(3):532–538

    PubMed  Google Scholar 

  2. Miyake Y, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006;24(3):519–523

    CAS  PubMed  Google Scholar 

  3. Al Chalabi T, Boccato S, Portmann BC, Mcfarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45(4):575–583

    PubMed  Google Scholar 

  4. Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23(9):1347–1353

    CAS  PubMed  Google Scholar 

  5. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21(5):866–871

    CAS  PubMed  Google Scholar 

  6. Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 1995;19(6):699–708

    CAS  PubMed  Google Scholar 

  7. Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cancado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009;43(4):350–356

    PubMed  Google Scholar 

  8. Werner M, Bjornsson E, Prytz H, Lindgren S, Almer S, Broome U, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42(8):986–991

    PubMed  Google Scholar 

  9. Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101(3):556–560

    CAS  PubMed  Google Scholar 

  10. Heneghan MA, Norris SM, O’Grady JG, Harrison PM, Mcfarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48(1):97–102

    CAS  PubMed  Google Scholar 

  11. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004;5(3):266–271

    CAS  PubMed  Google Scholar 

  12. Fusconi M, Vannini A, Dall’Aglio AC, Pappas G, Cassani F, Ballardini G, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2005;22(10):951–955

    CAS  PubMed  Google Scholar 

  13. Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, Murphy D, Shums Z, et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity 2006;39(4):341–348

    CAS  PubMed  Google Scholar 

  14. Ben-Ari Z, Broida E, Monselise Y, Kazatsker A, Baruch J, Pappo O, et al. Syncytial giant-cell hepatitis due to autoimmune hepatitis type II (LKM1+) presenting as subfulminant hepatitis. Am J Gastroenterol 2000;95(3):799–801

    CAS  PubMed  Google Scholar 

  15. Devaney K, Goodman ZD, Ishak KG. Postinfantile giant-cell transformation in hepatitis. Hepatology 1992;16(2):327–333

    CAS  PubMed  Google Scholar 

  16. Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002;6(3):685–705

    PubMed  Google Scholar 

  17. Burt AD, Portmann BC, Ferrell LD, MacSween R. Autoimmune hepatitis. In Pathology of the Liver. Edinburgh: Churchill Livingstone; 2007. 493–517

  18. Feld JJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42(1):53–62

    PubMed  Google Scholar 

  19. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001;32(5):428–430

    CAS  PubMed  Google Scholar 

  20. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40(4):646–652

    CAS  PubMed  Google Scholar 

  21. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004;39(6):1631–1638

    PubMed  Google Scholar 

  22. Johnson PJ, Mcfarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18(4):998–1005

    CAS  PubMed  Google Scholar 

  23. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929–938

    CAS  PubMed  Google Scholar 

  24. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169–176

    PubMed  Google Scholar 

  25. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008;48(5):1540–1548

    PubMed  Google Scholar 

  26. Yeoman AD, Westbrook RH, Al-Chalabi T, Carey I, Heaton ND, Portmann BC, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009;50(2):538–545

    PubMed  Google Scholar 

  27. Wiegard C, Schramm C, Lohse AW. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis 2009;29(3):254–261

    PubMed  Google Scholar 

  28. Roozendaal C, de Jong MA, van den Berg AP, van Wijk RT, Limburg PC, Kallenberg CG. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000;32(5):734–741

    CAS  PubMed  Google Scholar 

  29. Roozendaal C, Kallenberg CG. Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases. Hepatogastroenterology 1999;46(30):3034–3040

    CAS  PubMed  Google Scholar 

  30. Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000;95(11):3238–3241

    CAS  PubMed  Google Scholar 

  31. Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro P, Dommergues JP, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004;2(9):825–830

    PubMed  Google Scholar 

  32. Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355(9214):1510–1515

    CAS  PubMed  Google Scholar 

  33. Kanzler S, Weidemann C, Gerken G, Lohr HF, Galle PR, Meyer zum Buschenfelde KH, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999;31(4):635–640

    CAS  PubMed  Google Scholar 

  34. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21(1):78–83

    CAS  PubMed  Google Scholar 

  35. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1(7806):735–737

    CAS  PubMed  Google Scholar 

  36. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35(1):75–81

    PubMed  Google Scholar 

  37. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99(8):1510–1516

    PubMed  Google Scholar 

  38. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008;48(3):863–870

    PubMed  Google Scholar 

  39. Lohse AW, zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29(4):1078–1084

    CAS  PubMed  Google Scholar 

  40. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000;33(4):537–542

    CAS  PubMed  Google Scholar 

  41. Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002;97(5):1191–1197

    PubMed  Google Scholar 

  42. Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005;25(3):311–320

    PubMed  Google Scholar 

  43. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002;36(6):1393–1399

    PubMed  Google Scholar 

  44. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006;6(3):244–251

    CAS  PubMed  Google Scholar 

  45. Bertolino P, Klimpel G, Lemon SM. Hepatic inflammation and immunity: a summary of a conference on the function of the immune system within the liver. Hepatology 2000;31(6):1374–1378

    CAS  PubMed  Google Scholar 

  46. Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44(2):400–406

    CAS  PubMed  Google Scholar 

  47. Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006;44(1):85–90

    PubMed  Google Scholar 

  48. Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008;14(3):331–337

    PubMed  Google Scholar 

  49. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14(2–3):325–331

    CAS  PubMed  Google Scholar 

  50. McNair AN, Moloney M, Portmann BC, Williams R, Mcfarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998;93(5):777–784

    CAS  PubMed  Google Scholar 

  51. van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33(4):543–548

    PubMed  Google Scholar 

  52. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359(9301):150–157

    PubMed  Google Scholar 

  53. Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol 2008;29(11):514–522

    CAS  PubMed  Google Scholar 

  54. Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200(11):1511–1517

    CAS  PubMed  Google Scholar 

  55. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33(3):544–553

    CAS  PubMed  Google Scholar 

  56. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34(4 Pt 1):659–865

    CAS  PubMed  Google Scholar 

  57. Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008;47(3):949–957

    CAS  PubMed  Google Scholar 

  58. O’Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008;48(2):550–556

    PubMed  Google Scholar 

  59. Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002;6(3):707–725

    PubMed  Google Scholar 

  60. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6(4):379–388

    CAS  PubMed  Google Scholar 

  61. Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30(6):1374–1380

    CAS  PubMed  Google Scholar 

  62. Anderson G, Jenkinson WE, Jones T, Parnell SM, Kinsella FA, White AJ, et al. Establishment and functioning of intrathymic microenvironments. Immunol Rev 2006;209:10–27

    PubMed  Google Scholar 

  63. Su MA, Anderson MS. Aire: an update. Curr Opin Immunol 2004;16(6):746–752

    CAS  PubMed  Google Scholar 

  64. Su MA, Giang K, Zumer K, Jiang H, Oven I, Rinn JL, et al. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest 2008;118(5):1712–1726

    CAS  PubMed  Google Scholar 

  65. Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol 2004;40(6):904–909

    CAS  PubMed  Google Scholar 

  66. Vogel A, Liermann H, Harms A, Strassburg CP, Manns MP, Obermayer-Straub P. Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology 2001;33(5):1047–1052

    CAS  PubMed  Google Scholar 

  67. Czaja AJ, Santrach PJ, Breanndan MS. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001;46(1):140–147

    CAS  PubMed  Google Scholar 

  68. Mieli-Vergani G, Vergani D. Immunological liver diseases in children. Semin Liver Dis 1998;18(3):271–279

    CAS  PubMed  Google Scholar 

  69. Lohse AW, Lohr H, Bilo K, Zumbuschenfelde KHM. Recognition and regulation of LKM-specific T-cell clones in LKM-positive autoimmune hepatitis. Hepatology 1994;20:A144.

    Google Scholar 

  70. Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22(4):353–364

    CAS  PubMed  Google Scholar 

  71. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev 2003;2(5):241–247

    CAS  PubMed  Google Scholar 

  72. Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in liver diseases. Clin Rev Allergy Immunol 2000;18(2):127–139

    CAS  PubMed  Google Scholar 

  73. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354(1):54–66

    CAS  PubMed  Google Scholar 

  74. Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008;205(6):1409–1422

    CAS  PubMed  Google Scholar 

  75. Horwitz MS, Sarvetnick N. Viruses, host responses, and autoimmunity. Immunol Rev 1999;169:241–253

    CAS  PubMed  Google Scholar 

  76. Costa-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8(6):639–646

    Google Scholar 

  77. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24(2):179–189

    CAS  PubMed  Google Scholar 

  78. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8(9):950–957

    CAS  PubMed  Google Scholar 

  79. Costa-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8(9):942–949

    Google Scholar 

  80. Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008;205(6):1447–1461

    CAS  PubMed  Google Scholar 

  81. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126(6):1121–1133

    CAS  PubMed  Google Scholar 

  82. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28(1):29–39

    CAS  PubMed  Google Scholar 

  83. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008;105(28):9721–9726

    CAS  PubMed  Google Scholar 

  84. Veldhoen M, Hirota K, Christensen J, O’Garra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009;206(1):43–49

    CAS  PubMed  Google Scholar 

  85. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008;21(1):102–116

    CAS  PubMed  Google Scholar 

  86. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201(2):233–240

    CAS  PubMed  Google Scholar 

  87. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314(5804):1461–1463

    CAS  PubMed  Google Scholar 

  88. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103(9):1345–1352

    CAS  PubMed  Google Scholar 

  89. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8(5):500–558

    CAS  PubMed  Google Scholar 

  90. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180(11):7423–7430

    CAS  PubMed  Google Scholar 

  91. Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009;157(2):261–270

    CAS  PubMed  Google Scholar 

  92. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101(5):455–458

    CAS  PubMed  Google Scholar 

  93. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531–562

    CAS  PubMed  Google Scholar 

  94. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6(4):345–352

    CAS  PubMed  Google Scholar 

  95. Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005;201(11):1793–1803

    CAS  PubMed  Google Scholar 

  96. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203(7):1693–1700

    CAS  PubMed  Google Scholar 

  97. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057–1061

    CAS  PubMed  Google Scholar 

  98. Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80. J Immunol 1998;161(8):3919–3924

    CAS  PubMed  Google Scholar 

  99. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31(1):49–53

    CAS  PubMed  Google Scholar 

  100. Longhi MS, Hussain MJ, Bogdanos DP, Quaglia A, Mieli-Vergani G, Ma Y, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007;46(2):472–484

    CAS  PubMed  Google Scholar 

  101. Longhi MS, Meda F, Wang P, Samyn M, Mieli-Vergani G, Vergani D, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008;47(2):581–591

    CAS  PubMed  Google Scholar 

  102. Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006;176(7):4484–4491

    CAS  PubMed  Google Scholar 

  103. Mayo MJ, Mosby JM, Jeyarajah R, Combes B, Khilnani S, Al-halimi M, et al. The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver Int 2006;26(2):187–196

    CAS  PubMed  Google Scholar 

  104. Grant AJ. Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol 2002;160(4):1445–1455

    CAS  PubMed  Google Scholar 

  105. Moritoki Y, Lian ZX, Ohsugi Y, Ueno Y, Gershwin ME. B cells and autoimmune liver diseases. Autoimmun Rev 2006;5(7):449–457

    CAS  PubMed  Google Scholar 

  106. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31(6):1231–1238

    CAS  PubMed  Google Scholar 

  107. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15(2):215–221

    Google Scholar 

  108. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27(4):507–515

    CAS  PubMed  Google Scholar 

  109. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23(2):116–123

    PubMed  Google Scholar 

  110. Czaja AJ, Carpenter HA. Autoimmune hepatitis. In Portmann BC, Ferrell LD, editors. MacSween’s Pathology of the Liver. Edinburgh: Churchill Livingstone; 2007. 493–517

    Google Scholar 

  111. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983;85(3):713–717

    CAS  PubMed  Google Scholar 

  112. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51(5):968–975

    CAS  PubMed  Google Scholar 

  113. Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis 2009;29(3):273–285

    CAS  PubMed  Google Scholar 

  114. Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel W, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25(5):927–934

    CAS  PubMed  Google Scholar 

  115. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8(6):585–590

    Article  CAS  PubMed  Google Scholar 

  116. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119(5):1312–1316

    CAS  PubMed  Google Scholar 

  117. Rebollo BJ, Cifuentes MC, Pinar MA, Caunedo AA, Salas HE, Jimenez-Saenz M, et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999;91(9):630–638

    Google Scholar 

  118. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994;21(6):1040–1047

    CAS  PubMed  Google Scholar 

  119. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987;93(4):890–893

    CAS  PubMed  Google Scholar 

  120. van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90(5):771–776

    PubMed  Google Scholar 

  121. Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis—report of three cases. Z Gastroenterol 1997;35(7):571–578

    CAS  PubMed  Google Scholar 

  122. Stern RB, Wilkinson SP, Howorth PJ, Williams R. Controlled trial of synthetic d-penicillamine and prednisone in maintenance therapy for active chronic hepatitis. Gut 1977;18(1):19–22

    CAS  PubMed  Google Scholar 

  123. Stern RB, Wilkinson SP, Williams R. Proceedings: controlled trial of d-penicillamine therapy in chronic active hepatitis. Gut 1976;17(5):390

    CAS  PubMed  Google Scholar 

  124. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29(6):990–993

    CAS  PubMed  Google Scholar 

  125. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30(6):1381–1386

    CAS  PubMed  Google Scholar 

  126. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18(5):321–326

    PubMed  Google Scholar 

  127. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371–375

    CAS  PubMed  Google Scholar 

  128. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009;51(1):156–160

    CAS  PubMed  Google Scholar 

  129. Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103(12):3063–3070

    CAS  PubMed  Google Scholar 

  130. Santos ES, Arosemena LR, Raez LE, O’Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006;26(5):625–629

    CAS  PubMed  Google Scholar 

  131. Zaja F, De VS, Mazzaro C, Sacco S, Damiani D, De MG, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101(10):3827–3834

    CAS  PubMed  Google Scholar 

  132. Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20(1):23–28

    CAS  PubMed  Google Scholar 

  133. Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005;80(11):1560–1564

    CAS  PubMed  Google Scholar 

  134. Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006;38(7):2308–2310

    CAS  PubMed  Google Scholar 

  135. Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001;68(4):292–294

    CAS  PubMed  Google Scholar 

  136. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102(5):1930

    CAS  PubMed  Google Scholar 

  137. Weiler-Normann C, Wiegard C, Schramm C, Lohse AW. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol 2009;104(11):2877–2878

    PubMed  Google Scholar 

  138. Germano V, Picchianti DA, Baccano G, Natale E, Onetti MA, Priori R, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64(10):1519–1520

    CAS  PubMed  Google Scholar 

  139. Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26(4):578–581

    PubMed  Google Scholar 

  140. Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007;187(9):524–526

    PubMed  Google Scholar 

  141. Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol 2009;34(3):421–422

    CAS  PubMed  Google Scholar 

  142. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatol Treat 2003;14(4):229–232

    CAS  Google Scholar 

  143. Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2008;27(12):1597–1598

    PubMed  Google Scholar 

  144. Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat 2005;16(5–6):347–349

    CAS  Google Scholar 

  145. Morgan AW, Hale G, Rebello PR, Richards SJ, Gooi HC, Waldmann H, et al. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM 2008;101(4):299–306

    CAS  PubMed  Google Scholar 

  146. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007;46(7):1140–1147

    CAS  Google Scholar 

  147. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59(Suppl 1):i21–i27

    CAS  PubMed  Google Scholar 

  148. Drewe E, Powell RJ. Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002;55(2):81–85

    CAS  PubMed  Google Scholar 

  149. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S4–S10

    PubMed  Google Scholar 

  150. Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still’s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 2007;25(5):758–759

    CAS  PubMed  Google Scholar 

  151. van den Berg WB. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 2000;59(Suppl 1):i81–4.

    PubMed  Google Scholar 

  152. Genovese M, Van Den Bosch F, Roberson S, Bojin S, Biagini I, Ryan P, et al. LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum (Epub 2010 Jan 21)

  153. Durez P, et al. AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial. Ann Rheum Dis 2010;68(Suppl 3) (abstract LB.002)

  154. Cinamon G, Matloubian M, Lesneski MJ, Xu Y, Low C, Lu T, et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 2004;5(7):713–720

    CAS  PubMed  Google Scholar 

  155. Kahan BD. FTY720: from bench to bedside. Transplant Proc 2004;36(2 Suppl):531S–43S

    CAS  PubMed  Google Scholar 

  156. Rosen H, Sanna G, Alfonso C. Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev 2003;195:160–177

    CAS  PubMed  Google Scholar 

  157. Cyster JG. Lymphoid organ development and cell migration. Immunol Rev 2003;195:5–14

    CAS  PubMed  Google Scholar 

  158. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008;8(10):753–763

    CAS  PubMed  Google Scholar 

  159. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate—modifiers of lymphocyte migration. N Engl J Med 2006;355(11):1088–1091

    CAS  PubMed  Google Scholar 

  160. Bohler T, Budde K, Neumayer HH, Waiser J. Novel mediators of FTY720 in human lymphocytes. Transplantation 2005;79(4):492–495

    PubMed  Google Scholar 

  161. Ledgerwood LG, Lal G, Zhang N, Garin A, Esses SJ, Ginhoux F, et al. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol 2008;9(1):42–53

    CAS  PubMed  Google Scholar 

  162. Kaneko T, Murakami T, Kawana H, Takahashi M, Yasue T, Kobayashi E. Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem Biophys Res Commun 2006;345(1):85–92

    CAS  PubMed  Google Scholar 

  163. Andersen KG, Butcher T, Betz AG. Specific immunosuppression with inducible Foxp3-transduced polyclonal T cells. PLoS Biol 2008;6(11):e276

    PubMed  Google Scholar 

  164. Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 2009;131(2):298–307

    CAS  PubMed  Google Scholar 

  165. Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009;106(12):4793–4798

    CAS  PubMed  Google Scholar 

  166. Koenen HJ, Smeets RL, Vink PM, van Rijseen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008;112(6):2340–2352

    Google Scholar 

  167. Trowsdale J, Betz AG. Mother’s little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 2006;7(3):241–246

    CAS  PubMed  Google Scholar 

  168. Aluvihare VR, Kallikourdis M, Betz AG. Tolerance, suppression and the fetal allograft. J Mol Med 2005;83(2):88–96

    PubMed  Google Scholar 

  169. Oo YH, Neuberger J. Use of mycophenolate in the treatment of autoimmune hepatitis. Liver Int 2005;25(4):687–691

    CAS  PubMed  Google Scholar 

  170. Miyake T, Miyaoka H, Abe M, Furukawa S, Shigematsu S, Furukawa E, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36(2):139–142

    PubMed  Google Scholar 

  171. Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009;29(3):286–296

    PubMed  Google Scholar 

  172. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis 2009;29(3):315–330

    PubMed  Google Scholar 

  173. Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int 2009;22(2):144–152

    PubMed  Google Scholar 

  174. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004;18(1):62–69

    PubMed  Google Scholar 

  175. Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl 2009;15(Suppl 2):S25–S34

    Article  PubMed  Google Scholar 

  176. Duclos-Vallee JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52(6):893–897

    PubMed  Google Scholar 

  177. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12(12):1813–1824

    PubMed  Google Scholar 

  178. Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl 2001;7(4):285–291

    CAS  PubMed  Google Scholar 

  179. Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7(4):302–310

    CAS  PubMed  Google Scholar 

  180. Salcedo M, Vaquero J, Banares R, Rodriguez-Mahou M, Alvarez E, Vicario JL, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35(2):349–356

    CAS  PubMed  Google Scholar 

  181. Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351(9100):409–413

    CAS  PubMed  Google Scholar 

  182. Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34(3):464–470

    CAS  PubMed  Google Scholar 

  183. D’Antiga L, Dhawan A, Portmann B, Francavilla R, Rela M, Heaton N, et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002;73(1):80–84

    PubMed  Google Scholar 

  184. Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Sakurai T, Minamiguchi S, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004;78(1):128–135

    PubMed  Google Scholar 

  185. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40(1):3–7

    PubMed  Google Scholar 

  186. Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007;7(4):955–963

    CAS  PubMed  Google Scholar 

  187. Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2007;45(2):222–227

    CAS  PubMed  Google Scholar 

  188. Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol 2000;33(1):163–166

    CAS  PubMed  Google Scholar 

  189. Lohse AW, Obermayer-Straub P, Gerken G, Brunner S, Altes U, Dienes HP, et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson’s disease—possible association with a steroid-resistant transplant rejection episode. J Hepatol 1999;31(1):149–155

    CAS  PubMed  Google Scholar 

  190. Riva S, Sonzogni A, Bravi M, Bertani A, Alessio MG, Candusso M, et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl 2006;12(4):573–577

    PubMed  Google Scholar 

  191. Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008;14(6):861–871

    PubMed  Google Scholar 

  192. Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006;81(3):488–490

    PubMed  Google Scholar 

  193. Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006;12(5):827–830

    PubMed  Google Scholar 

  194. Berardi S, Lodato F, Gramenzi A, D’Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56(2):237–242

    CAS  PubMed  Google Scholar 

  195. Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl 2004;10(9):1166–1172

    PubMed  Google Scholar 

  196. Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant Proc 2005;37(9):3968–3969

    CAS  PubMed  Google Scholar 

  197. Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E, Tiscar JL, Banares R, Clemente G, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: long-term follow-up after liver transplantation. Transplantation 2007;83(8):1126–1129

    CAS  PubMed  Google Scholar 

  198. Salcedo M, Rodriguez-Mahou M, Rodriguez-Sainz C, Rincon D, Alvarez E, Vicario JL, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione-S-transferase T1 antibodies after liver transplantation. Liver Transpl 2009;15(5):530–539

    PubMed  Google Scholar 

  199. Yoshizawa K, Shirakawa H, Ichijo T, Umemura T, Tanaka E, Kiyosawa K, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transplant 2008;22(3):385–390

    Article  PubMed  Google Scholar 

  200. Grammatikopoulos. AASLD; 2010 (abstract 706)

  201. Richter A, Grabhorn E, Helmke K, Manns MP, Ganschow R, Burdelski M. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transplant 2007;21(3):427–432

    PubMed  Google Scholar 

  202. Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl 2007;13(7):943–946

    PubMed  Google Scholar 

  203. Herzog D, Soglio DB, Fournet JC, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl 2008;14(7):946–955

    PubMed  Google Scholar 

  204. Evans HM. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006;43(5):1109–1117

    PubMed  Google Scholar 

  205. Syn WK. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007;13(7):984–989

    PubMed  Google Scholar 

  206. Hubscher S. What does the long-term liver allograft look like for the pediatric recipient? Liver Transpl 2009;15(Suppl 2):S19–S24

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Liver Research, NIHR Biomedical Research Unit, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

    Ye H. Oo & David H. Adams

  2. Department of Pathology, University of Birmingham Medical School, Wolfson Drive, Edgbaston, Birmingham, B15 2TT, UK

    Stefan G. Hubscher

Authors
  1. Ye H. Oo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan G. Hubscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David H. Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David H. Adams.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oo, Y.H., Hubscher, S.G. & Adams, D.H. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int 4, 475–493 (2010). https://doi.org/10.1007/s12072-010-9183-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-010-9183-5

Keywords

Search

Navigation